Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14899290 | 0.87 | PKM (0.53) | HCAR2PKMHTR3AKDM4EALDH1A1 | |
| SCHEMBL12701252 | 0.83 | PKM (0.71) | HCAR2PKMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5237714 | 0.83 | HTR1A (0.51) | HCAR2HTR3AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12701294 | 0.83 | MAP4K4 (0.53) | HCAR2PKM | |
| SCHEMBL29931500 | 0.80 | KDM4E (0.68) | HCAR2HTR3AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5239212 | 0.80 | KDM4E (0.68) | HCAR2HTR3AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28139867 | 0.74 | HCAR2 (0.41) | HCAR2PKMHTR3A | |
| SCHEMBL5128181 | 0.73 | MAP4K4 (0.43) | HCAR2HTR3AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12701264 | 0.73 | KDM4E (0.58) | HCAR2PKMHTR3AKDM4EALDH1A1 | |
| SCHEMBL12701240 | 0.73 | KDM4E (0.52) | HCAR2PKMKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | HCAR2 69/4885PKM 2585/4885HTR3A 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.